The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant cell generally displayed moderate to strong cytoplasmic positivity. Malignant lymphomas and skin cancers along with several testicular and renal cancers were weakly stained or negative.
Most malignant tissues showed weak to moderate cytoplasmic staining. Malignant gliomas, thyroid cancers and a few cases of endometrial, ovarian and head & neck cancers showed strong immunoreactivity together with occasional cases in other cancers. Most malignant lymphomas and several prostate cancers were negative.
Malignant cells generally displayed moderate to strong cytoplasmic positivity. Most malignant carcinoids and lymphomas as well as several prostate cancer where weakly stained or negative.
A majority of malignancies showed weak to moderate cytoplasmic positivity. A majority of malignant gliomas and endometrial cancers as well as several malignant melanomas were strongly stained. Several prostate and testicular cancers were negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
